Integer Holdings
ITGR
126.59
+0.12
+0.09%
Integer Holdings
US · ITGR
#2239 by market cap
Listed 1970
126.59
+0.12
+0.09%
Live - 5344 symbols - heartbeat 349s ago
· 2026-10-07 19:54
After-hours
126.57
-0.02%
- Market cap
- 4.30B
- P/E (TTM)i
- 34.68
- P/Bi
- 2.50
- EPSi
- 2.89
- Div yieldi
- 0.00%
- 52W posi
- 100%
Reader sentiment
Are you bullish or bearish on ITGR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.92, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.98% YoY
Margins
- Gross margin
- 26.99%
- Operating margin
- 12.90%
- Net margin
- 5.55%
Key ratios & quality
- Enterprise valuei
- 5.49B
- PEG ratioi
- 2.21
- Altman Z-Scorei
- 2.92
PEG uses trailing P/E against the 3-year net income growth rate (15.70%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.26B | 1.07B | 1.22B | 1.33B | 1.56B | 1.72B | 1.85B |
| Gross profit | 362.67M | 355.01M | 285.71M | 336.97M | 345.76M | 409.89M | 459.01M | 500.39M |
| Selling & admin expenses | 142.44M | 138.70M | 109.01M | 141.42M | 158.05M | 173.17M | 185.20M | 211.75M |
| Research & development | 48.60M | 46.53M | 48.47M | 51.99M | 59.76M | 61.97M | 53.43M | 49.50M |
| Operating profit | 170.11M | 165.97M | 123.55M | 143.57M | 127.95M | 174.75M | 220.39M | 239.14M |
| Pretax profit | 61.12M | 105.19M | 86.21M | 101.06M | 68.68M | 105.38M | 147.56M | 125.40M |
| Tax | 14.08M | 13.98M | 8.95M | 8.04M | 8.93M | 16.24M | 26.51M | 22.57M |
| Net profit | 167.96M | 96.34M | 77.26M | 96.81M | 66.38M | 90.65M | 119.90M | 102.81M |
| Basic EPS | 5 | 3 | 2 | 3 | 2 | 3 | 4 | 3 |
| Diluted EPS | 5.15 | 2.92 | 2.33 | 2.91 | 1.99 | 2.69 | 3.36 | 2.89 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 437.39M | 476.49M | 467.69M | 472.06M | 439.58M | 464.11M |
| Gross profit | 120.32M | 129.15M | 126.16M | 124.76M | 109.60M | 112.94M |
| Selling & admin expenses | 38.55M | 39.30M | 36.48M | 97.42M | 45.02M | 44.21M |
| Research & development | 14.20M | 14.24M | 10.95M | 10.11M | 16.24M | 11.28M |
| Operating profit | 56.13M | 62.90M | 65.90M | 54.55M | 35.47M | 44.61M |
| Pretax profit | -13.00M | 45.60M | 45.99M | 46.81M | 20.35M | 23.29M |
| Tax | 9.47M | 8.59M | 6.31M | -1.80M | 3.85M | -314.00K |
| Net profit | -22.49M | 37.01M | 39.68M | 48.61M | 16.51M | 23.61M |
| Basic EPS | -1 | 1 | 1 | 1 | 0 | 1 |
| Diluted EPS | -0.66 | 1.04 | 1.11 | 1.38 | 0.48 | 0.69 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 416.25M | 415.40M | 412.94M | 452.98M | 558.30M | 617.67M | 671.12M | 770.10M |
| Cash & ST investments | 25.57M | 13.54M | 49.21M | 17.89M | 24.27M | 23.67M | 46.54M | 17.16M |
| Inventory | 190.08M | 167.26M | 149.32M | 155.70M | 208.77M | 229.10M | 247.13M | 253.74M |
| Total assets | 2.33B | 2.35B | 2.37B | 2.58B | 2.79B | 2.94B | 3.08B | 3.41B |
| Total current liabilities | 164.57M | 179.08M | 156.19M | 159.63M | 223.75M | 220.97M | 227.17M | 232.04M |
| Short-term debt | 37.50M | 45.01M | 45.93M | 25.72M | 29.64M | 10.42M | 21.91M | 16.94M |
| Long-term debt | 888.01M | 777.27M | 693.76M | 812.88M | 907.07M | 959.93M | 980.15M | 1.19B |
| Total liabilities | 1,266,188,000.00 | 1,200,605,000.00 | 1,100,802,000.00 | 1,227,518,000.00 | 1,376,930,000.00 | 1,423,611,000.00 | 1,458,756,000.00 | 1,663,934,000.00 |
| Total equity | 1.06B | 1.15B | 1.27B | 1.35B | 1.42B | 1.52B | 1.62B | 1.75B |
| Retained earnings | 344.50M | 440.26M | 517.52M | 614.32M | 680.70M | 771.35M | 891.25M | 994.06M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 702.20M | 737.43M | 778.12M | 770.10M | 774.76M | 810.64M |
| Cash & ST investments | 31.71M | 23.14M | 58.94M | 17.16M | 8.12M | 21.38M |
| Inventory | 260.10M | 266.44M | 263.54M | 253.74M | 284.48M | 288.06M |
| Total assets | 3.30B | 3.37B | 3.40B | 3.41B | 3.41B | 3.42B |
| Total current liabilities | 206.40M | 216.03M | 209.82M | 232.04M | 206.34M | 217.14M |
| Short-term debt | 8.72M | 8.92M | 9.13M | 16.94M | 8.11M | 8.21M |
| Long-term debt | 1.24B | 1.20B | 1.19B | 1.19B | 1.25B | 1.24B |
| Total liabilities | 1,690,999,000.00 | 1,667,398,000.00 | 1,651,473,000.00 | 1,663,934,000.00 | 1,714,827,000.00 | 1,704,848,000.00 |
| Total equity | 1.61B | 1.70B | 1.75B | 1.75B | 1.70B | 1.72B |
| Retained earnings | 868.76M | 905.77M | 945.45M | 994.06M | 1.01B | 1.03B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 167.30M | 165.36M | 181.34M | 156.67M | 116.38M | 180.21M | 205.21M | 196.15M |
| Depreciation & amortization | 88.99M | 77.90M | 79.32M | 81.37M | 91.99M | 98.84M | 111.03M | 130.67M |
| Free cash flow | 122.39M | 117.16M | 129.90M | 103.20M | 41.65M | 60.28M | 99.85M | 105.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | 0 | 0 | -50.01M |
| Ending cash balance | 25.57M | 13.54M | 49.21M | 17.89M | 24.27M | 23.67M | 46.54M | 17.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 31.28M | 43.86M | 65.60M | 55.42M | 24.70M | 59.74M |
| Depreciation & amortization | 29.83M | 32.29M | 33.04M | 35.51M | 35.01M | 34.54M |
| Free cash flow | 6.06M | 24.86M | 45.31M | 28.89M | 737.00K | 37.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | -50.00M | 0 |
| Ending cash balance | 31.71M | 23.14M | 58.94M | 17.16M | 8.12M | 21.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 17.19 | 8.71 | 6.38 | 7.37 | 4.79 | 6.17 | 7.64 | 6.11 |
| ROA %i | 6.49 | 4.12 | 3.27 | 3.91 | 2.47 | 3.16 | 3.98 | 3.17 |
| ROIC %i | 10.89 | 7.10 | 5.49 | 5.85 | 4.26 | 5.35 | 6.15 | 4.59 |
| 5-year avg ROE %i | 6.95 | 6.77 | 8.25 | 9.58 | 8.89 | 6.68 | 6.47 | 6.42 |
| EBIT margin %i | 13.20 | 12.54 | 11.59 | 10.87 | 8.33 | 9.92 | 11.64 | 8.72 |
| FCF / sales %i | 10.07 | 9.31 | 12.10 | 8.45 | 3.03 | 3.78 | 5.80 | 5.67 |
| Current ratioi | 2.53 | 2.32 | 2.64 | 2.84 | 2.50 | 2.80 | 2.95 | 3.32 |
| Quick ratioi | 1.28 | 1.29 | 1.59 | 1.69 | 1.44 | 1.54 | 1.74 | 2.05 |
| Debt / assetsi | 39.78 | 36.52 | 32.78 | 35.08 | 36.10 | 35.78 | 35.85 | 38.49 |
| LT debt / equityi | 83.74 | 70.66 | 57.56 | 64.97 | 69.08 | 68.62 | 66.80 | 74.18 |
| Interest coveragei | 1.62 | 3.00 | 3.26 | 4.20 | 2.97 | 3.10 | 3.82 | 4.45 |
| Revenue CAGR (3Y) %i | 14.93 | 5.37 | -1.87 | 0.17 | 1.90 | 13.16 | 12.02 | 11.67 |
| Net income CAGR (3Y) %i | -- | 152.83 | 5.03 | -16.78 | -11.68 | 5.47 | 7.39 | 15.70 |
| FCF CAGR (3Y) %i | -- | 35.69 | 8.37 | -5.53 | -29.16 | -22.58 | -1.10 | 36.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | 4.91 | 5.08 | 5.16 | 6.11 | 8.58 | 7.50 |
| ROA %i | 2.40 | 2.54 | 2.65 | 3.17 | 4.23 | 3.78 |
| ROIC %i | 3.99 | 4.02 | 4.03 | 4.59 | 5.63 | 5.19 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 9.27 | 9.02 | 8.71 | 8.72 | 10.25 | 9.14 |
| FCF / sales %i | 6.38 | 6.70 | 6.56 | 5.67 | 5.38 | 6.07 |
| Current ratioi | 3.40 | 3.41 | 3.71 | 3.32 | 3.75 | 3.73 |
| Quick ratioi | 1.99 | 1.98 | 2.27 | 2.05 | 2.19 | 2.21 |
| Debt / assetsi | 41.08 | 39.19 | 38.59 | 38.49 | 40.49 | 39.86 |
| LT debt / equityi | 83.77 | 77.03 | 74.58 | 74.18 | 80.93 | 78.91 |
| Interest coveragei | 3.10 | 3.48 | 3.83 | 4.45 | 6.04 | 5.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Cardio & Vascular is the largest reported line at 60.40% of revenue, across 3 reported segments.
- Cardiac Rhythm Management & Neuromodulation follows at 37.43%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Cardio & Vascular60.40%
Cardiac Rhythm Management & Neuromodulation37.43%
Other markets2.17%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.